April 24, 2018 / 11:11 AM / 7 months ago

BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration

April 24 (Reuters) - Immunovaccine Inc:

* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER

* IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTE'S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE

* IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL

* IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below